Drugs / CS-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06745336 | Jun 2025 → Jun 2027 expected | graying of hair, precocious | Applied Biology, Inc. | Not yet recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-10-29 | Artery Therapeutics, Inc. | Artery is presenting Phase 1 Single Ascending Dose data from the successful and recently completed Clinical Trial ATI-CS-001 at CTAD24 conference in Madrid, Spain. arterytx.com ↗ |
| 2023-11-01 | Artery Therapeutics, Inc. | Artery is proud to inform that the ATI-CS-001 study (NCT05965414) has been approved by regulatory authorities, ethics committee with screening commencing November 1, 2023. arterytx.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CS-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06745336 ↗ |
| Modality | Small molecule | “CS-001 is a small molecule” NCT06745336 ↗ |
| Route | Topical | “CS-001 Topical Treatment” NCT06745336 ↗ |